Full-Time

Medical Writer

Confirmed live in the last 24 hours

Calyxo

Calyxo

201-500 employees

Develops medical devices for kidney stone treatment

Compensation Overview

$120k - $140k/yr

Mid

No H1B Sponsorship

Pleasanton, CA, USA

Hybrid (minimum 3 days a week in the office)

Category
Technical Writing
Content & Writing
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Calyxo referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Advanced degree, such as a PhD or MD with proven biostatistical training and application, in a relevant scientific discipline (e.g., Life Sciences, Pharmaceutical Sciences, Clinical Research, or similar fields)
  • Minimum of 3.5 to 5 years of experience in scientific affairs, clinical research, or drug development within the medical device, pharmaceutical, or biotech industry, preferably in urology, nephrology, or related fields
  • Strong publication record required with at least 1 first author publication. Please include publication record as part of your resume or CV
  • Proven experience in scientific communications, including peer-reviewed publications, abstracts, and scientific presentations
  • Demonstrated ability to interact with industry professionals and KOLs
  • Experience managing clinical pipelines, regulatory submissions, and R&D projects a plus
  • Experience in competitive intelligence and interpreting market trends a plus
  • Strong strategic thinking and interpersonal skills with the ability to work in a fast-paced, dynamic start-up environment
  • Exceptional written and verbal communication skills, with the ability to translate complex scientific data into clear, concise messaging for diverse audiences
  • Ability to work independently with sound autonomous decision making
  • Work location: Pleasanton, CA. Hybrid (minimum 3 days a week in the office)
  • Travel: Up to 25%
  • Full-time employment
  • Responsible for performing all duties in compliance with FDA’s Quality System Regulation (QSR), ISO13485, the Canadian Medical Device Regulations, and all other international regulatory requirements with which the company complies
  • Compliance with relevant county, state, and Federal rules regarding vaccinations
Responsibilities
  • Implementation and project management of the company’s scientific podium and publication plan with expected contribution to strategy
  • Creation and timely submission of high-quality peer-reviewed publications, abstracts and presentations covering all categories listed below
  • Build relationships with key opinion leaders (KOLs) to foster research collaborations and ensure timely abstract and publication submissions. In-person support of all KOL presentations at meetings is required
  • Development of deliverables including but not limited to white papers, op eds, and clinical summaries
  • Collaborate with clinical operations to support trial design, develop protocols, and ensure clinical data supports the company’s scientific objectives
  • Foster communication and alignment with clinical operations and other stakeholders to ensure trial execution is aligned with podium and publication plans. Work cross functionally to adjust timelines if/when milestones may be at risk elevating to leadership as needed
  • Support R&D teams and external partners to ensure scientific rigor in the development of preclinical research to clinical trials
  • Project management of the company’s preclinical research strategy, inclusive of adjoining communication plan, with expected contribution to strategy
  • Provide medical writing for all FDA submissions
  • Write Clinical Evaluation Reports (CERs); oversee accompanying comprehensive literature review
  • Collaborate with the marketing team to translate scientific data into compelling marketing messages and develop scientific content for promotional materials as needed
  • Support medical communications review by ensuring that all marketing materials are scientifically accurate and compliant with regulations
  • Support the scientific analysis of competitive landscape, identifying trends, emerging technologies, and potential threats in the urinary stone market
  • Project management of the company’s health economics outcomes research strategy, inclusive of adjoining communication plan, with expected contribution to strategy
  • In-depth participation of healthcare claims analyses including benchmark research and vendor identification
  • Continuously liaise with the reimbursement team to ensure clinical pipeline and outcomes meet foreseeable needs; align podium and publication plan accordingly
  • Attend in-person team building events and contribute meaningfully
  • Attend society meetings as requested to ensure a successful podium plan and seek out immersive research presentations
  • Contribute to a culture of innovation, collaboration and scientific excellence
  • Perform additional activities as assigned by supervisor
Desired Qualifications
  • Experience managing clinical pipelines, regulatory submissions, and R&D projects a plus
  • Experience in competitive intelligence and interpreting market trends a plus

Calyxo develops medical devices specifically designed to treat kidney stones. Their products focus on improving the effectiveness and safety of treatment options available to urologists. By collaborating with leading urologists, Calyxo ensures that their devices meet the real clinical needs of healthcare providers. Unlike many competitors, Calyxo emphasizes a strong partnership with medical professionals to enhance patient care and clinical outcomes. The company's goal is to provide advanced solutions that make kidney stone treatment more efficient and effective, ultimately improving the overall experience for both patients and healthcare providers.

Company Size

201-500

Company Stage

Series D

Total Funding

$97.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for the redesigned CVAC System boosts market credibility and adoption.
  • Rising prevalence of kidney stones expands Calyxo's potential customer base.
  • Series D funding of $50M supports further innovation and market expansion.

What critics are saying

  • Emerging competition may impact Calyxo's market share in kidney stone treatments.
  • Economic downturns could reduce healthcare spending on new medical devices.
  • Rapid technological advancements require Calyxo to continuously innovate to stay competitive.

What makes Calyxo unique

  • Calyxo's CVAC System offers superior stone clearance compared to standard URS.
  • The company focuses on minimally invasive kidney stone treatments with high patient satisfaction.
  • Calyxo collaborates with leading urologists to enhance R&D and device innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

-4%
Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

Finsmes
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

Business Wire
Jul 6th, 2022
Calyxo Raises $32.7 Million In Series C Financing To Support Novel Approach To Treating Kidney Stones

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently